DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2258367/gear-up-for-biogen-biib-q1-earnings-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2258367 Apr 19, 2024 - Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024. 0

https://www.zacks.com/stock/news/2221865/biogen-inc-biib-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2221865 Feb 06, 2024 - Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2224200/ionis-ions-eplontersen-gets-fast-track-tag-for-new-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2224200 Feb 09, 2024 - The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). 0

https://www.zacks.com/stock/news/2225441/here-s-what-key-metrics-tell-us-about-biogen-inc-biib-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2225441 Feb 13, 2024 - The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. 0

https://www.fool.com/earnings/call-transcripts/2024/02/13/biogen-biib-q4-2023-earnings-call-transcript/?source=iedfolrf0000001 Feb 13, 2024 - BIIB earnings call for the period ending December 31, 2023. 0

https://www.zacks.com/stock/news/2227123/sage-therapeutics-sage-q4-earnings-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2227123 Feb 15, 2024 - Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise. 0

https://www.fool.com/earnings/call-transcripts/2024/04/24/biogen-biib-q1-2024-earnings-call-transcript/?source=iedfolrf0000001 Apr 24, 2024 - BIIB earnings call for the period ending March 31, 2024. 0

https://www.zacks.com/stock/news/2262685/biotech-stock-roundup-biib-bmy-s-q1-earnings-incy-s-acquisition-updates-from-vrtx?cid=CS-ZC-FT-analyst_blog|earnings_article-2262685 Apr 25, 2024 - Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement. 0

https://www.zacks.com/stock/news/2263560/sage-therapeutics-sage-q1-earnings-miss-sales-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2263560 Apr 26, 2024 - Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line. 0